Moleculin
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5300 Memorial Dr Ste 950, Houston, Texas...Phone Number
(713) 300-5160Website
www.moleculin.comRevenue
-Stock Symbol
MBRXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Moleculin
Moleculin Biotech is a late-stage clinical pharmaceutical company developing Annamycin (naxtarubicin), a "next-generation" anthracycline, in a pivotal Phase 2/3 MIRACLE trial combined with cytarabine for relapsed/refractory acute myeloid leukemia. Technologies originate from licenses with UT MD Anderson Cancer Center. Interim June 2026 data showed higher remission rates versus control, though not yet statistically significant; final analysis pending across ~282 planned subjects.Explore more
Moleculin Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Moleculin your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Moleculin, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Moleculin is spiking on competitors!
Funding: Get notified immidiatlly once Moleculin has new funding data
Check if Moleculin has recently received funding, and reach out quickly before it becomes old news!
Click to see if Moleculin had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Moleculin
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Moleculin launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Moleculin recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Moleculin as Masked Content
Find 2 more new buyers
Compare Similar Companies to Moleculin
Compare insights from companies similar to Moleculin, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Moleculin financials insights
Gather financial insights about Moleculin, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$1.4M
2016
Stock Offering
$9.2M
Moleculin Tech Stack
A closer look at the technologies used by Moleculin
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Moleculin News & Media
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial
HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the second quarter ended June 30, 2026, and highlighted continued progress in its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in relapsed or refractory acute myeloid leukemia (AML).Moleculin Announces Pricing of $9.3 Million Public Offering
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof), and warrants (the “Common Warrants”) to purchase up to 37,130,001 shares of common stock at a combined public offering price of $0.75 per share of common stock (or pre-funded warrant in lieu thereof) and associatedMoleculin’s MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients
Prior venetoclax failure — a setting in which published salvage remission rates are approximately 13% and median survival approximately 2.4 months — shows no adverse impact on blinded composite remission rates as MIRACLE approaches the end of Part AMoleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
HOUSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that Walter Klemp, Chairman and Chief Executive Officer of Moleculin, participated in a Virtual Investor “What This Means” segment.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Moleculin
Sign Up For FreeTo access detailed company insights
Moleculin Biotech is a late-stage clinical pharmaceutical company developing Annamycin (naxtarubicin), a "next-generation" anthracycline, in a pivotal Phase 2/3 MIRACLE trial combined with cytarabine for relapsed/refractory acute myeloid leukemia. Technologies originate from licenses with UT MD Anderson Cancer Center. Interim June 2026 data showed... Read More
